Skip to content

Guardian Pharmacy Services GRDN Proceeds from sale of assets

Proceeds from sale of assets at other companies

Cencora logo
CencoraCOR

Other financials

Income statement

See full
Revenue$336.6M+2.2%
Gross profit$76.3M+18.6%
Operating income$17.7M+35.9%
Net income$13.3M+40.7%
EPS (diluted)$0.21+40.0%

Balance sheet

See full
Cash & equivalents$64.9M+364%
Total debt$36.9M+29.6%
Total equity$232.4M+42.4%
Total assets$426.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M-65.5%
CapEx$495.0K-78.0%
Free cash flow$34.1M+69.8%

Valuation

See full
Market cap$2.48B+80.1%
Enterprise value$2.45B+76.1%
P/E46.8×
P/S1.7×+0.6×

Profitability

See full
Gross margin20.9%+1.1pp
Operating margin5.3%
Net margin3.6%+2.1pp

Returns & leverage

See full
Return on equity26.8%
Debt / equity0.2×0.0×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Guardian Pharmacy Services in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.

The official record: Guardian Pharmacy Services’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardian Pharmacy Services's proceeds from sale of assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardian Pharmacy Services's proceeds from sale of assets?
Guardian Pharmacy Services (GRDN) reported proceeds from sale of assets of $0 in Q1 2026.
How has Guardian Pharmacy Services's proceeds from sale of assets changed year-over-year?
Guardian Pharmacy Services's proceeds from sale of assets decreased by 100.0% year-over-year, from $260K to $0.